Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR
Oncologist
.
2015 May;20(5):570.
doi: 10.1634/theoncologist.2013-0419erratum.
Authors
Myung-Ju Ahn
,
Sang-We Kim
,
Byoung-Chul Cho
,
Jin Seok Ahn
,
Dae Ho Lee
,
Jong-Mu Sun
,
Dan Massey
,
Miyoung Kim
,
Yang Shi
,
Keunchil Park
PMID:
25956899
PMCID:
PMC4425374
DOI:
10.1634/theoncologist.2013-0419erratum
No abstract available
Publication types
Published Erratum